The joint venture will market Teva’s generics and Takeda’s off-patent drugs in Japan. It will operate as an independent company with its own Board of Directors, Chief Executive Officer, and Executive Leadership team and is expected to start operating in the second quarter of 2016. The two companies will split ownership 51% for Teva and 49% for Takeda.

The partners said the new venture will combine Teva’s generics portfolio with Takeda’s Japanese distribution network and brand recognition. They added that the business model is in line with the Japanese Government’s push to limit healthcare spending by increasing market penetration for generics. In response to the high amount of spending on medicines in Japan [1], the government has set the objectives to reach 80% generics penetration by the end of 2020.

Related article
Europe–Japan cooperation on generics and biosimilars regulation

Reference
1.    GaBI Online - Generics and Biosimilars Initiative. Prescribing and dispensing generics in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Dec 11]. Available from: www.gabionline.net/Generics/Research/Prescribing-and-dispensing-generics-in-Japan

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.